MedPath

Impact of primary prevention and chemoprevention on the promotion of prostate cancer and the risk of developing clinically manifested prostate cancer: A prospective cohort study

Not Applicable
Conditions
prostate cancer
Registration Number
JPRN-UMIN000017789
Lead Sponsor
The Japanese Foundation for Prostate Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
Male
Target Recruitment
887
Inclusion Criteria

Not provided

Exclusion Criteria

1) having past or present history of prostate cancer 2) having severe complications (caridiac disease, interstitial pneumonia, bleeding tendency, uncontrollable hypertension, diabetes mellitus, etc.) 3) having uncontrolled other malignant disease (excluding carcinoma in situ, skin cancer and no evidence of recurrence more than 3 years after the treatment) 4) having any inappropriate factor judged by investigators

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in tumor marker (PSA, ratio of free to total PSA) and developing clinically manifested prostate cancer
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath